Onxeo further strengthens its board of directors with two seasoned personalities from the healthcare sector


Dr Robert L. Coleman, Scientific Director of the American Oncology Network and Dr Jacques Mallet, old Senior Vice President Portfolio analysis/Business strategy at Sanofi, join the companyBoard of directors as independent members

Paris (France), Oct. 14, 2021 (GLOBE NEWSWIRE) – Onxeo HER. (Euronext Growth Paris: ALONX, Nasdaq First North: ONXEO), “Onxeo”, a clinical-stage biotechnology company specializing in the development of innovative drugs targeting the response to tumor DNA damage (DDR) in oncology, announced today ‘ hui the appointment of Dr Robert L Coleman and Dr Jacques Mallet as independent members of the Board of Directors.

Robert L. Coleman, MD, is the Scientific Director of the US Oncology Network (“The Network”), one of America’s largest networks dedicated to advancing high quality, based on cancer care and research. evidence, with more than 400 ongoing clinical studies involving more than 1400 physicians. Prior to joining the US Oncology Network in 2020, Dr Coleman served as Executive Director of MD Anderson’s Cancer Network Research Program. In addition, he has been a professor and also held the Ann Rife Cox Chair in Gynecology at the University of Texas. Dr. Coleman’s work has been featured in over 500 publications examining the role of new therapies in ovarian cancer, such as the incorporation of PARP inhibitors into the treatment strategy.

Jacques Mallet, MD, was SVP – Head of Portfolio Analytics / Corporate Strategy and a member of the Sanofi Executive Leadership Team and is currently a member of the board of directors of several listed and private companies in the health technology sector. He brings to Onxeo more than 30 years of experience in the pharmaceutical industry in the areas of R&D, pipeline development and business strategy, as well as a unique knowledge gained in the life sciences at the both in Europe and the United States as a venture capitalist. Previously, Mr. Mallet had been Head of Investments at Auriga Partners, a private equity firm specializing in life sciences in France, and held senior positions in global consulting firms such as Monitor Deloitte and Accenture.

Dr Robert L. Coleman, New independent member of the Onxeo Board of Directors, declared: “I am very honored to to rejoin the Board of Directors of Onxeo. Like cancer specialist, I dedicated my all career to improviseis lying the path we to treat many types of cancer and I am delighted to bring my experience to support the development of Onxeo and its international pipeline, in particular through clinical development in the USA. Based on the large body of data collected so far by the team, I have believe AsiDNAâ„¢ could change Cancer treatment paradigm, especially in some selected combinations and represents a promising way to help the patients in need.

Doctor Jacques Mallet, New independent member of the Onxeo Board of Directors, added: “I am delighted To have the opportunity to join this strong group of directors to support the team in Development and growth of the company. i was impressed by AsiDNAâ„¢ and the many development opportunities this potential breakthrough compound. I am now looking forward to supporting the highly professional Onxeo teams to better design the next steps to ensure optimal value creation for the company.

Shefali Agarwal, Chairwomen of the Board of Directors of Onxeo, commented: We are proud have such distinct experts join our Plank and benefit from their rich experience in the healthcare industry. Dr Coleman is an internationally recognized leader in the field of ovarian cancer who strongly contributed to development numerous innovative treatments for this very aggressive form of cancer. Dr Mallet brings three decades of experience as a strategist and investor in the healthcare sector, which is a major asset for Onxeo development. Their additoinal context combine exitstanding clinical research and management of international pharmaceutical companies Make them a great fit for Onxeo as we continue to grow and improve our research program around AsiDNAâ„¢.

Judith Greciet, Chief Executive Officer of Onxeo, concluded: I am delighted to welcome these two remarkable experts on our board of directors. With the recent appointment of Shefali Agarwal as our President, they will be an active support for the Company ambitious development program, including its expansion inTo United States.

About Onxeo

Onxeo (Euronext Paris, NASDAQ Copenhagen: ONXEO) is a clinical-stage biotechnology company developing innovative oncology drugs targeting tumor DNA binding functions through unique mechanisms of action in the research area of ​​damage response to DNA (DDR). The Company is focused on bringing first-class or disruptive compounds at an early stage from translational research to clinical proof of concept, a value-creating inflection point attractive to potential partners.

Platoâ„¢ is Onxeo’s chemical platform of oligonucleotides acting as decoy agonists, which generates innovative new compounds and expands the Company’s product pipeline.

AsiDNAâ„¢, the first platON compoundâ„¢, is a first-class and clinically highly differentiated candidate for DNA damage response (DDR). Its decoy and agonist mechanism acting upstream of several DDR pathways results in distinctive anti-tumor properties, including the ability to prevent or abrogate tumor resistance to targeted therapies such as PARP inhibitors and a strong synergy with damaging agents. ‘Tumor DNA such as radio / chemotherapy. AsiDNAâ„¢ is currently undergoing combined clinical studies in hard-to-treat solid tumors.

OX401 is a new drug candidate for platONâ„¢, optimized to be a potent PARP agonist acting both on the response to DNA damage and on the activation of the immune response, without inducing resistance. OX401 is the subject of preclinical proof of concept studies, alone and in combination with immunotherapies.

For Following information, please visit www.onxeo.com.

Forward-looking statements
This communication expressly or impliedly contains certain forward-looking statements concerning Onxeo and its business. Such statements involve certain risks, uncertainties and other known and unknown factors, which could cause the actual results, financial position, performance or achievements of Onxeo to differ materially from future results, performances or achievements expressed or under – understood by these forward-looking statements. . Onxeo is providing this communication as of that date and does not undertake to update any forward-looking statements contained in this document as a result of new information, future events or otherwise. For a discussion of the risks and uncertainties that could cause Onxeo’s actual results, financial position, performance or achievements to differ from those contained in forward-looking statements, please refer to the risk factors described in the document. most recent reference document of the Company or in any other periodic financial report and in any other press release, which are available free of charge on the websites of the Group of the Company (www.onxeo.com) and / or the AMF (www.amf-france.org).

Contacts

Onxeo
Valérie Leroy,
Investor Relations
[email protected]
+33 1 45 58 76 00

Media relations
Nicolas merigeau
NewCap
[email protected]
+33 1 44 71 94 98

Investor Relations / Strategic Communication
Dušan Orešanský / Emmanuel Huynh
NewCap
[email protected]
+33 1 44 71 94 92

Certified Advisor for Nasdaq First North
Capital partner
www.kapitalpartner.dk
[email protected]
+45 89 88 78 46


Leave a Reply

Your email address will not be published.